Age-Related Macular Degeneration (AMD) Market Analysis by Top Companies, Trends and Future Prospects Details for Business Development

The market is experiencing growth due to the rising geriatric population, growing pipeline for AMD therapeutics, surging chronic disease prevalence, and increasing healthcare expenditure. Age-related macular degeneration is a retinal disorder, which is indicated by changes in the fundus of the eye. It commonly affects the elderly, in which, first, the central vision becomes blurred, which ultimately leads to blindness.

Explore Report with Detailed TOC at:
https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market

Based on type, the AMD market is bifurcated into wet AMD and dry AMD. Between the two, during the historical period (2012–2015), the larger revenue in the market was generated by the wet AMD type. This type of AMD is caused due to the abnormal growth of blood vessels from the choroid layer, which is situated beneath the macula. It is also known as neovascular macular degeneration, and even though it accounts for only 10–15% of AMD cases, it is expected to be the faster growing category in the forecast period.

Download Report Sample at:
https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-market/report-sample

The AMD market is witnessing the trend of the rising awareness about the disease. Various activities, campaigns, and programs are being conducted by NGOs, healthcare providers, and optometrists’ associations to sensitize people about the disease and its course of treatment. February is celebrated as the National AMD awareness month as a measure to encourage people to educate themselves about the disease and understand the risk factors and be aware in case they exhibit any of the symptoms. The awareness about the disease has also resulted in increased funding for research related to the AMD.

With the rising awareness about the disease, more funding is being allocated in the research and development of AMD therapeutics. This is resulting in the increase in the number of AMD pipeline drugs. Currently, the U.S. Food and Drug Administration has not approved any drug in the age-related macular degeneration (AMD) market for dry AMD. Therefore, the need to investigate more compounds with possible therapeutics properties is rising. Some of the major investigational compounds in the market are Roche/Genentech’s lampalizumab, MacuCLEAR’s MC1101, and Allergan’s brimonide implant.

Therefore, the market for AMD is predicted to register remarkable growth in the forecast period with the rising prevalence of this disease and surging geriatric population.